Stock Analysis
10x Genomics, Inc. (TXG) Stock Analysis
10x Genomics, Inc. (TXG) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
10x Genomics, Inc. (TXG) currently has an AIQ Score of 50/100, indicating a neutral setup. Sentiment is the strongest factor at 68/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TXG at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $62.65 |
| AIQ Score | 50/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $7.61B |
| P/E Ratio | -101.66 |
| Forward P/E | — |
| EPS | -$0.14 |
| Revenue TTM | $151.04M |
| Dividend Yield | 0.00% |
| Beta | 2.04 |
| Volume | 1.47M |
| 52-week range | $11.16-$66.94 |
| RSI 14 | 59.09 |
| 50-Day SMA | $50.87 |
| 200-Day SMA | $28.94 |
| Analyst Price Target | $43.73 |
| Next Earnings | Nov 5, 2026 |
TXG
OverviewTXG Stock Analysis Summary
10x Genomics, Inc. (TXG) currently has an AIQ Score of 50/100, indicating a neutral setup. Sentiment is the strongest factor at 68/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, TXG has AIQ Score of 50/100 with Sentiment base of 68/100 and fading Value at 34/100. Wait for component alignment before adding exposure.
Sentiment (68/100) leads while Value (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.90% stock move · TXG classified in Medical - Healthcare Information Services.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TXG Bullish or Bearish Right Now?
TXG currently has a neutral overall setup. Sentiment is the strongest factor at 68/100, while Value is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 67/100.
- - Price is +23.15% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (33 vs 5).
- - Value is the current constraint at 34/100.
- - Risk Resilience is weak at 38/100.
- - Analyst target implies -30.20% downside from the latest quote.
Current Consensus
TXG's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 7 neutral, and 5 sell votes. TXG's 14-day RSI is 59.09, which places the stock in a constructive momentum range. TXG's beta is 2.04, indicating greater market sensitivity than the broad market.
What Changed in TXG?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the TXG Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TXG Decision Framework
Public evidence layers, setup checks, and risk context for 10x Genomics, Inc..
10x Genomics, Inc. (TXG) Stock Analysis
10x Genomics, Inc. has an AIQ Score of 50/100 in a Neutral regime. Sentiment is strongest at 68/100. Beta is 2.04, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TXG is in a Neutral AIQ regime with score 50/100. |
| Signal Conflict | The primary conflict is that sentiment leads at 68/100 while value lags at 34/100. |
| Factor Evidence | Momentum 67/100 · Value 34/100 · Quality 59/100 · Risk 38/100 · Sentiment 68/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Sentiment is the strongest factor at 68/100.
Momentum is 67/100 and RSI (14) is 59.1.
TXG is in a Neutral regime at 50/100.
Risk factor is 38/100 with beta 2.04 and annual volatility 72.52%.
Current conflict: sentiment leads at 68/100 while value lags at 34/100.
TXG Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TXG Fundamentals
TXG valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TXG Technical Analysis
TXG technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TXG Stock Catalysts
Track TXG earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TXG Dividend Analysis
TXG dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TXG Financial Data
TXG revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TXG Risk Analysis
TXG volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TXG Stock News
TXG stock news, market tone, recent headlines, and catalyst context.
TXG vs Life Sciences / Tools / CRO Peers
Current peer cohort: TXG · ZTS · A · CDNA · CERT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TXG Current stock | 50/100 | 34/100 | 67/100 | 38/100 | 2.42 | 72.52% | Current |
| ZTS Zoetis | 64/100 | 62/100 | 63/100 | 55/100 | -1.78 | 37.61% | TXG vs ZTS |
| A Agilent Technologies | 56/100 | 37/100 | 61/100 | 63/100 | 0.53 | 32.70% | TXG vs A |
| CDNA CareDx | 61/100 | 27/100 | 73/100 | 44/100 | 2.18 | 71.66% | TXG vs CDNA |
| CERT Certara | 55/100 | 53/100 | 61/100 | 54/100 | -0.24 | 59.87% | TXG vs CERT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 4, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 5, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TXG
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TXG
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TXG Stock FAQ
What is TXG stock price today?
10x Genomics, Inc.'s current stock price is $62.65. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TXG bullish or bearish right now?
TXG's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TXG's market cap?
TXG's market cap is $7.61B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TXG's current P/E ratio?
TXG's current P/E ratio is -101.66 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TXG's RSI?
TXG's 14-day RSI is 59.09 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TXG above its 50-day and 200-day moving averages?
TXG is 23.15% from its 50-day SMA and 116.49% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TXG's next earnings date?
TXG's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TXG pay a dividend?
TXG's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.